Anaphylm Resubmission Sets New PDUFA Date of March 2027; Approval Delayed Beyond Original Timeline

What happened

Aquestive Therapeutics announced that the FDA has accepted its resubmission for Anaphylm, with a new PDUFA goal date of March 16, 2027, a substantial delay from the prior January 31, 2026 target. The company emphasized that Anaphylm would be the first and only oral rescue medication for severe allergic reactions if approved, and that commercial preparations remain on track for a potential launch. Ex-U.S. regulatory efforts are advancing, with a Health Canada submission expected in Q4 2026 and an EU filing planned for Q1 2027. However, the resubmission itself implies the original application was not approved, likely due to a complete response letter, forcing a year-long setback. The company did not disclose financial details for Q3 2026 in this release, but the extended timeline raises concerns about cash runway and the burden of ongoing launch investments.

Implication

The FDA's acceptance of the resubmission is a necessary step but does not guarantee approval; the new PDUFA date of March 2027 means Aquestive must fund operations for an additional year without Anaphylm sales. With a leveraged balance sheet and shrinking legacy revenues, the company may need to raise additional capital, likely diluting shareholders, or draw down the RTW facility with further royalty encumbrances. The ex-U.S. filings are positive but will not generate near-term revenue, and competition from neffy continues to intensify. Given the prolonged timeline, the probability of the bear scenario in our master report has increased, and the stock's valuation should reflect a lower probability of near-term commercial success. Investors should monitor cash burn, financing activities, and any updates on the label and commercial positioning as key indicators of the company's ability to reach launch.

Thesis delta

The delay in Anaphylm approval directly validates our bear thesis, which emphasized regulatory uncertainty and the risk of a complete response letter. The resubmission acceptance does not eliminate this risk, and the extended timeline increases the likelihood of further dilution and financial distress. As such, we maintain our POTENTIAL SELL rating with increased conviction, and would consider lowering our attractive entry price as the risk-reward skew becomes more unfavorable.